Hims and Hers Expands Consumer-Focused Digital Health Platform
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is building a consumer-first digital health platform aimed at expanding access to personalized, ongoing care through a technology-driven model. Its platform integrates telehealth consultations, electronic medical records, digital prescriptions and pharmacy fulfillment, allowing patients to access treatment for a range of conditions including sexual health, dermatology, hair loss, hormone health, mental health and weight management. The subscription-based model enables continuous engagement between patients and providers while supporting personalized treatment plans and follow-up care through its mobile and web interfaces.
HIMS has recently expanded its ecosystem with new specialties and proactive health offerings. These include a new category in men’s health focused on low testosterone treatments, as well as a menopause and perimenopause specialty on the Hers platform aimed at addressing underserved women’s health needs. In addition, the launch of Labs allows customers to track key biomarkers and receive doctor-developed action plans, while the introduction of a multi-cancer early detection test expands access to preventative screening and earlier diagnosis.
Alongside product expansion, Hims & Hers is scaling its global footprint. The company has entered Canada following the acquisition of a local digital health platform, expanded its weight-loss program in the U.K. and announced plans to acquire Eucalyptus, which is expected to extend its presence into additional international markets and strengthen its global consumer health platform.
TEM and MED Expanding Data-Driven Healthcare Platforms
Tempus AI, Inc. TEM is advancing precision medicine by integrating artificial intelligence (AI) with large multimodal healthcare datasets to enable more personalized diagnostics and treatment decisions. Tempus AI leverages its platform of clinical, molecular and imaging data to develop intelligent diagnostics that help physicians match patients with more effective therapies. Recently, Tempus AI launched innovations such as the Paige Predict digital pathology solution and the HRD-RNA algorithm to improve biomarker identification, while also expanding collaborations with partners like Merck and leading health systems to accelerate AI-driven oncology research and screening initiatives.
Medifast, Inc. MED is repositioning itself as a metabolic health company through its science-based, coach-guided wellness platform centered on the OPTAVIA system. Medifast combines structured nutrition plans, clinically informed products and behavioral coaching to help individuals improve metabolic health rather than focusing solely on short-term weight loss. Recently, Medifast strengthened this strategy by enabling eligible OPTAVIA programs to be reimbursed through HSA and FSA plans, expanding access to its metabolic health solutions while continuing to develop new systems and products aimed at supporting long-term metabolic balance and sustainable lifestyle change.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 33.6% over the past year, underperforming the industry’s decline of 23.6%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.8X is lower than the industry’s average of 3.5X and its five-year median of 2.7X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a flat performance compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
VALERO ENERGY CORP <VLO.N>: JEFFERIES CUTS TARGET PRICE TO $394 FROM $401
VALERO ENERGY CORP : JEFFERIES CUTS TARGET PRICE TO $394 FROM $401
Gold prices rise Rs 1,500/10g; silver up Rs 3,100/kg ahead of US economic data, softer yields. Buy, sell or hold?
The Shopify Stock Rally Isn't Done: Chart of the Week -- Barrons.com
By Doug Busch Shopify is no longer a pandemic-era growth story that simply failed to slow down. It is compounding at a pace few software platforms its size still manage. In the second quarter of 2026, sales on its platform rose 32%. That was the fifth straight quarter of growth exceeding 30%. Merchants are also using more of Shopify's own tools, from payments to Shop Pay, and new channels like AI shopping agents are starting to increase demand. The simple bull case is that the stock already commands a huge share of independent online commerce, and that position should become more valuable as more buying moves through its checkout. A rule of market mechanics is that the vast majority of an individual security's gain is driven by its underlying sector. Within technology, software has staged a robust recovery, joining semiconductors to power the broader sector higher. The iShares Expanded Tech-Software Sector ETF has maintained an upward trajectory since its mid-April lows, though the advance from $74 to $112 has been choppy as bulls repeatedly stepped in to defend when necessary. Breadth across large-cap software has expanded significantly, with 24 constituents surging over 20% over the past three months. During that same three-month window, Shopify generated outstanding relative strength, advancing 36%, more than doubling the IGV's 17% gain over the same period. Expect the stock's outperformance to persist as software momentum broadens. Let's examine the daily and monthly charts to outline the technical drivers behind this thesis. Looking at the daily chart, the ratio chart against the IGV shows persistent outperformance extending back to mid-May. The stock is riding an eight-session winning streak, during which price action cleared a double-bottom-with-handle pivot at $151.39. Within this broader base, the stock recorded a bullish golden cross in late August and successfully filled its Sept. 10 price gap, tracing back to its Aug. 4 session, the day before a powerful earnings reaction sent the stock surging 17% hi
Crypto prices
More
